High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T. E. Witzig; B. Laplant; T. M. Habermann; E. McPhail; D. J. Inwards; I. N. Micallef; J. P. Colgan; G. S. Nowakowski; S. M. Ansell; P. B. Johnston

doi:10.1038/BCJ.2017.57

High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T. E. Witzig
, B. Laplant
, T. M. Habermann
, E. McPhail
, D. J. Inwards
, I. N. Micallef
, J. P. Colgan
, G. S. Nowakowski
, S. M. Ansell
, P. B. Johnston

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Article number	e576
Journal	Blood cancer journal
Volume	7
Issue number	6
DOIs	https://doi.org/10.1038/BCJ.2017.57
State	Published - 2017

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/BCJ.2017.57

Cite this

Witzig, T. E., Laplant, B., Habermann, T. M., McPhail, E., Inwards, D. J., Micallef, I. N., Colgan, J. P., Nowakowski, G. S., Ansell, S. M., & Johnston, P. B. (2017). High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood cancer journal, 7(6), Article e576. https://doi.org/10.1038/BCJ.2017.57

Witzig, TE, Laplant, B, Habermann, TM , McPhail, E, Inwards, DJ, Micallef, IN, Colgan, JP, Nowakowski, GS , Ansell, SM & Johnston, PB 2017, 'High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)', Blood cancer journal, vol. 7, no. 6, e576. https://doi.org/10.1038/BCJ.2017.57

@article{126596619ce24a9aa44aa7d8d57d8ddf,

title = "High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)",

author = "Witzig, \{T. E.\} and B. Laplant and Habermann, \{T. M.\} and E. McPhail and Inwards, \{D. J.\} and Micallef, \{I. N.\} and Colgan, \{J. P.\} and Nowakowski, \{G. S.\} and Ansell, \{S. M.\} and Johnston, \{P. B.\}",

note = "Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA025224 and U10CA180790. Support was also provided in part by Novartis.",

year = "2017",

doi = "10.1038/BCJ.2017.57",

language = "English (US)",

volume = "7",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma

T2 - updated results from NCCTG N1085 (Alliance)

AU - Witzig, T. E.

AU - Laplant, B.

AU - Habermann, T. M.

AU - McPhail, E.

AU - Inwards, D. J.

AU - Micallef, I. N.

AU - Colgan, J. P.

AU - Nowakowski, G. S.

AU - Ansell, S. M.

AU - Johnston, P. B.

N1 - Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA025224 and U10CA180790. Support was also provided in part by Novartis.

PY - 2017

Y1 - 2017

UR - https://www.scopus.com/pages/publications/85046068829

UR - https://www.scopus.com/pages/publications/85046068829#tab=citedBy

U2 - 10.1038/BCJ.2017.57

DO - 10.1038/BCJ.2017.57

M3 - Letter

C2 - 28649983

AN - SCOPUS:85046068829

SN - 2044-5385

VL - 7

JO - Blood cancer journal

JF - Blood cancer journal

IS - 6

M1 - e576

ER -

High rate of event-free survival at 24 months with everolimus/ RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this